Imaging Recommendations for Diagnosis, Staging, and Management of Cancer of the Thyroid, Parathyroid, and Salivary Glands

Abstract

Thyroid cancer ranks as the leading endocrine malignancy in adults. The foundation for primary diagnosis of thyroid cancer is a high-resolution ultrasound (US) of the thyroid gland including US-guided fine-needle biopsy (FNB) of suspected thyroid nodules. Advanced cross-sectional imaging, including computed tomography (CT), magnetic resonance imaging, and positron emission tomography, can be useful in selected patients. The mainstay of treatment of thyroid cancer is surgery. It may be supplemented by radioactive iodine ablation/therapy in high-risk differentiated thyroid cancer. Radiology plays a crucial role in both diagnostic and posttreatment follow-up imaging. Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder with single parathyroid adenoma being its most common cause. The radiologist's aim in parathyroid imaging is to provide the clinician with an illustrative picture of the neck, locating lesions with respect to landmarks. Imaging helps in the detection of solitary versus multiglandular disease, ectopic and supernumerary glands with precise localization. US, nuclear imaging, and four-dimensional CT are the most commonly used imaging modalities for the preoperative localization of the parathyroid disease. Salivary gland tumors account for approximately 0.5% of all neoplasms, the most common location being the parotid gland (70%). Imaging is crucial in salivary gland tumors by defining its location, detecting malignant features, assessing local extension and invasion, staging the tumors according to the tumor-node-metastasis classification, and assessing the feasibility of surgery.

Keywords

Computed tomography - cross-sectional imaging - guidelines - head and neck cancer - magnetic resonance imaging - parathyroid imaging - salivary gland tumor - thyroid cancer - thyroid gland - ultrasound - thyroid gland - ultrasound

Publication History

Article published online:
04 May 2023

• References

• 1 Tufano RP, Clayman G, Heller KS. et al; American Thyroid Association Surgical Affairs Committee Writing Task Force. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid 2015; 25 (01) 15-27
• 2 Noone AM, Cronin KA, Altekruse SF. et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev 2017; 26 (04) 632-641
• 3 John AM, Jacob PM, Oommen R, Nair S, Nair A, Rajaratnam S. Our experience with papillary thyroid microcancer. Indian J Endocrinol Metab 2014; 18 (03) 410-413
• 4 Liu Y, Su L, Xiao H. Review of factors related to the thyroid cancer epidemic. Int J Endocrinol 2017; 2017: 5308635
• 5 Crnčić TB, Tomaš MI, Girotto N, Ivanković SG. Risk factors for thyroid cancer: what do we know so far?. Acta Clin Croat 2020; 59 (Suppl. 01) 66-72
• 6 Bonnefond S, Davies TF. Thyroid cancer-risks and causes. Oncol Hematol Rev 2014; 10 (02) 14451
• 7 Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13 (03) 184-199
• 8 Patel KN, Yip L, Lubitz CC. et al. The American Association of Endocrine Surgeons Guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg 2020; 271 (03) e21-e93
• 9 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 10 O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010; 15 (02) 146-156
• 11 Lechner MG, Hershman JM. Thyroid Nodules and Cancer in the Elderly. In: Endotext. South Dartmouth, MA: MDText.com, Inc.; 2000. PMID: 25905203.
• 12 Lee JY, Baek JH, Ha EJ. et al; Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology. 2020 imaging guidelines for thyroid nodules and differentiated thyroid cancer: Korean Society of Thyroid Radiology. Korean J Radiol 2021; 22 (05) 840-860
• 13 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26 (01) 1-133
• 14 Gharib H, Papini E, Paschke R. et al; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive Summary of recommendations. J Endocrinol Invest 2010; 33 (5, Suppl): 287-291
• 15 Perros P, Boelaert K, Colley S. et al; British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 2014; 81 (Suppl. 01) 1-122
• 16 Shin JH, Baek JH, Chung J. et al; Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol 2016; 17 (03) 370-395
• 17 Yi KH, Park YJ, Koong SS. et al. Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. Endocrinol Metab (Seoul) 2010; 25 (04) 270-297
• 18 www.nccn.org
• 19 Wells Jr SAJ, Asa SL, Dralle H. et al; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25 (06) 567-610
• 20 Bible KC, Kebebew E, Brierley J. et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid 2021; 31 (03) 337-386
• 21 Seib CD, Harari A, Conte FA, Duh QY, Clark OH, Gosnell JE. Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer. Surgery 2014; 156 (02) 394-398
• 22 Cibas ES, Ali SZ. The 2017 Bethesda System for reporting thyroid cytopathology. Thyroid 2017; 27 (11) 1341-1346
• 23 Birtwhistle R, Morissette K, Dickinson JA. et al; Canadian Task Force on Preventive Health Care. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care. CMAJ 2019; 191 (46) E1274-E1280
• 24 Morrison SA, Suh H, Hodin RA. The surgical management of thyroid cancer. Rambam Maimonides Med J 2014; 5 (02) e0008
• 25 Wong KT, Ahuja AT. Ultrasound of thyroid cancer. Cancer Imaging 2005; 5 (01) 157-166
• 26 Chng CL, Tan HC, Too CW. et al. Diagnostic performance of ATA, BTA and TIRADS sonographic patterns in the prediction of malignancy in histologically proven thyroid nodules. Singapore Med J 2018; 59 (11) 578-583
• 27 Gharib H, Papini E, Garber JR. et al; American association of clinical endocrinologists, American college of endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update appendix. Endocrine practice 2016; 22: 1-60
• 28 Lee YJ, Kim DW, Shin GW. et al. Comparison of ultrasonography features and K-TIRADS for isthmic and lobar papillary thyroid carcinomas: a single-center study. Front Endocrinol (Lausanne) 2020; 11: 328
• 29 Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. European thyroid association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EU-TIRADS. Eur Thyroid J 2017; 6 (05) 225-237
• 30 Tessler FN, Middleton WD, Grant EG. et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol 2017; 14 (05) 587-595
• 31 Grani G, Lamartina L, Ascoli V. et al. Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: toward the “right” TIRADS. J Clin Endocrinol Metab 2019; 104 (01) 95-102
• 32 Tessler FN, Middleton WD, Grant EG. et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee. J Amer Coll Radiol 2017; 14 (05) 587-595
• 33 Hoang JK, Branstetter IV BF, Gafton AR, Lee WK, Glastonbury CM. Imaging of thyroid carcinoma with CT and MRI: approaches to common scenarios. Cancer Imaging 2013; 13 (01) 128-139
• 34 Kebebew E, Clark OH. Differentiated thyroid cancer: “complete” rational approach. World J Surg 2000; 24 (08) 942-951
• 35 King AD. Imaging for staging and management of thyroid cancer. Cancer Imaging 2008; 8 (01) 57-69
• 36 Ahuja AT, Chow L, Chick W, King W, Metreweli C. Metastatic cervical nodes in papillary carcinoma of the thyroid: ultrasound and histological correlation. Clin Radiol 1995; 50 (04) 229-231
• 37 Yeh MW, Bauer AJ, Bernet VA. et al; American Thyroid Association Surgical Affairs Committee Writing Task Force. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 2015; 25 (01) 3-14
• 38 Kim MJ, Kim EK, Park SI. et al. US-guided fine-needle aspiration of thyroid nodules: indications, techniques, results. Radiographics 2008; 28 (07) 1869-1886 , discussion 1887
• 39 Bhatki AM, Brewer B, Robinson-Smith T, Nikiforov Y, Steward DL. Adequacy of surgeon-performed ultrasound-guided thyroid fine-needle aspiration biopsy. Otolaryngol Head Neck Surg 2008; 139 (01) 27-31
• 40 Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006; 91 (04) 1364-1369
• 41 Snozek CL, Chambers EP, Reading CC. et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 2007; 92 (11) 4278-4281
• 42 Boi F, Maurelli I, Pinna G. et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92 (06) 2115-2118
• 43 Tran Cao HS, Johnston LE, Chang DC, Bouvet M. A critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) registry. Surgery 2012; 152 (02) 145-151
• 44 Adam MA, Thomas S, Roman SA, Hyslop T, Sosa JA. Rethinking the current American Joint Committee on cancer TNM Staging system for medullary thyroid cancer. JAMA Surg 2017; 152 (09) 869-876
• 45 Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2018; 68 (01) 55-63
• 46 Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 2007; 245 (03) 366-378
• 47 Adam MA, Pura J, Goffredo P. et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol 2015; 33 (21) 2370-2375
• 48 Zaheer S, Tan A, Ang ES. et al. Post-thyroidectomy neck ultrasonography in patients with thyroid cancer and a review of the literature. Singapore Med J 2014; 55 (04) 177-182 , quiz 183
• 49 Schlumberger M, Berg G, Cohen O. et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004; 150 (02) 105-112
• 50 Pacini F, Molinaro E, Castagna MG. et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88 (08) 3668-3673
• 51 Wang LY, Ganly I. Post-treatment surveillance of thyroid cancer. Eur J Surg Oncol 2018; 44 (03) 357-366
• 52 Ito Y, Miyauchi A. Active surveillance of low-risk papillary thyroid microcarcinomas. Gland Surg 2020; 9 (05) 1663-1673
• 53 Bunch PM, Kelly HR. Preoperative imaging techniques in primary hyperparathyroidism: a review. JAMA Otolaryngol Head Neck Surg 2018; 144 (10) 929-937
• 54 Fraser WD. Hyperparathyroidism. Lancet 2009; 374 (9684): 145-158
• 55 Ruda JM, Hollenbeak CS, Stack Jr BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132 (03) 359-372
• 56 Yeh MW, Ituarte PH, Zhou HC. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013; 98 (03) 1122-1129
• 57 Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet 2018; 391 (10116): 168-178
• 58 Machado NN, Wilhelm SM. Diagnosis and evaluation of primary hyperparathyroidism. Surg Clin North Am 2019; 99 (04) 649-666
• 59 Palmér M, Adami HO, Bergström R, Jakobsson S, Akerström G, Ljunghall S. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987; 1 (8524): 59-62
• 60 Palmér M, Adami HO, Bergström R, Akerström G, Ljunghall S. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987; 102 (01) 1-7
• 61 Hedbäck G, Tisell LE, Bengtsson BÅ, Hedman I, Oden A. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990; 14 (06) 829-835 , discussion 836
• 62 Leifsson BG, Ahrén B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 1996; 81 (06) 2149-2153
• 63 Hedbäck G, Odén A. Increased risk of death from primary hyperparathyroidism—an update. Eur J Clin Invest 1998; 28 (04) 271-276
• 64 Yu N, Donnan PT, Flynn RW. et al; The Parathyroid Epidemiology and Audit Research Study (PEARS). Increased mortality and morbidity in mild primary hyperparathyroid patients. Clin Endocrinol (Oxf) 2010; 73 (01) 30-34
• 65 Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006; 140 (06) 874-881 , discussion 881–882
• 66 Zanocco KA, Wu JX, Yeh MW. Parathyroidectomy for asymptomatic primary hyperparathyroidism: a revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery 2017; 161 (01) 16-24
• 67 Bunch PM, Randolph GW, Brooks JA, George V, Cannon J, Kelly HR. Parathyroid 4D CT: what the surgeon wants to know. Radiographics 2020; 40 (05) 1383-1394
• 68 Rodgers SE, Hunter GJ, Hamberg LM. et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery 2006; 140 (06) 932-940 , discussion 940–941
• 69 Suh YJ, Choi JY, Kim SJ. et al. Comparison of 4D CT, ultrasonography, and 99mTc sestamibi SPECT/CT in localizing single-gland primary hyperparathyroidism. Otolaryngol Head Neck Surg 2015; 152 (03) 438-443
• 70 Kelly HR, Hamberg LM, Hunter GJ. 4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-naive and re-exploration patients. AJNR Am J Neuroradiol 2014; 35 (01) 176-181
• 71 Tian Y, Tanny ST, Einsiedel P. et al. Four-dimensional computed tomography: clinical impact for patients with primary hyperparathyroidism. Ann Surg Oncol 2018; 25 (01) 117-121
• 72 Yeh R, Tay YD, Tabacco G. et al. Diagnostic performance of 4D CT and Sestamibi SPECT/CT in localizing parathyroid adenomas in primary hyperparathyroidism. Radiology 2019; 291 (02) 469-476
• 73 Bahl M, Sepahdari AR, Sosa JA, Hoang JK. Parathyroid adenomas and hyperplasia on four-dimensional CT scans: three patterns of enhancement relative to the thyroid gland justify a three-phase protocol. Radiology 2015; 277 (02) 454-462
• 74 Sho S, Yilma M, Yeh MW. et al. Prospective validation of two 4D-CT-based scoring systems for prediction of multigland disease in primary hyperparathyroidism. AJNR Am J Neuroradiol 2016; 37 (12) 2323-2327
• 75 Raghavan P, Durst CR, Ornan DA. et al. Dynamic CT for parathyroid disease: are multiple phases necessary?. AJNR Am J Neuroradiol 2014; 35 (10) 1959-1964
• 76 Griffith B, Chaudhary H, Mahmood G. et al. Accuracy of 2-phase parathyroid CT for the preoperative localization of parathyroid adenomas in primary hyperparathyroidism. AJNR Am J Neuroradiol 2015; 36 (12) 2373-2379
• 77 Jason DS, Balentine CJ. Intraoperative decision making in parathyroid surgery. Surg Clin North Am 2019; 99 (04) 681-691
• 78 Wilhelm SM, Wang TS, Ruan DT. et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016; 151 (10) 959-968
• 79 Minisola S, Cipriani C, Diacinti D. et al. Imaging of the parathyroid glands in primary hyperparathyroidism. Eur J Endocrinol 2016; 174 (01) D1-D8
• 80 Parangi S, Pandian TK, Thompson G. Minimally invasive single gland parathyroid exploration. Surgery of the thyroid and parathyroid glands. Amsterdam, the Netherlands: Elsevier; 2021: 529-536
• 81 Stack Jr BC, Tolley NS, Bartel TB. et al. AHNS Series: do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. Head Neck 2018; 40 (08) 1617-1629
• 82 Schneider AB, Lubin J, Ron E. et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149 (06) 625-630
• 83 Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010; 74 (02) 134-148
• 84 Forrest J, Campbell P, Kreiger N, Sloan M. Salivary gland cancer: an exploratory analysis of dietary factors. Nutr Cancer 2008; 60 (04) 469-473
• 85 Kessler AT, Bhatt AA. Review of the major and minor salivary glands, part 2: neoplasms and tumor-like lesions. J Clin Imaging Sci 2018; 8: 48
• 86 Freling N, Crippa F, Maroldi R. Staging and follow-up of high-grade malignant salivary gland tumours: the role of traditional versus functional imaging approaches—a review. Oral Oncol 2016; 60: 157-166
• 87 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2020
• 88 Thoeny HC. Imaging of salivary gland tumours. Cancer Imaging 2007; 7 (01) 52-62
• 89 Wierzbicka M, Kopeć T, Szyfter W, Kereiakes T, Bem G. The presence of facial nerve weakness on diagnosis of a parotid gland malignant process. Eur Arch Otorhinolaryngol 2012; 269 (04) 1177-1182
• 90 Mantravadi AV, Moore MG, Rassekh CH. AHNS series: do you know your guidelines? Diagnosis and management of salivary gland tumors. Head Neck 2019; 41 (02) 269-280
• 91 Pfister DG, Spencer S, Adelstein D. et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18 (07) 873-898
• 92 Zheng N, Li R, Liu W, Shao S, Jiang S. The diagnostic value of combining conventional, diffusion-weighted imaging and dynamic contrast-enhanced MRI for salivary gland tumors. Br J Radiol 2018; 91 (1089): 20170707
• 93 Ma G, Zhu LN, Su GY. et al. Histogram analysis of apparent diffusion coefficient maps for differentiating malignant from benign parotid gland tumors. Eur Arch Otorhinolaryngol 2018; 275 (08) 2151-2157
• 94 Geiger JL, Ismaila N, Beadle B. et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol 2021; 39 (17) 1909-1941
• 95 Cermik TF, Mavi A, Acikgoz G, Houseni M, Dadparvar S, Alavi A. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med 2007; 32 (04) 286-291
• 96 WERING B. Neoplasms of the salivary glands. Atlas of head and neck pathology. 2008:582–91.
• 97 Lee YY, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumours. Eur J Radiol 2008; 66 (03) 419-436
• 98 Terhaard CH, Lubsen H, Van der Tweel I. et al; Dutch Head and Neck Oncology Cooperative Group. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004; 26 (08) 681-692 , discussion 692–693
• 99 Christe A, Waldherr C, Hallett R, Zbaeren P, Thoeny H. MR imaging of parotid tumors: typical lesion characteristics in MR imaging improve discrimination between benign and malignant disease. AJNR Am J Neuroradiol 2011; 32 (07) 1202-1207
• 100 Habermann CR, Arndt C, Graessner J. et al. Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible?. AJNR Am J Neuroradiol 2009; 30 (03) 591-596
• 101 Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M. Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology 2003; 226 (02) 345-354
• 102 Kim JY, Lee SW, Kim JS. et al. Diagnostic value of neck node status using 18F-FDG PET for salivary duct carcinoma of the major salivary glands. J Nucl Med 2012; 53 (06) 881-886
• 103 Digonnet A, Hamoir M, Andry G. et al. Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma. Eur Arch Otorhinolaryngol 2013; 270 (07) 1981-1989
• 104 Manikantan K, Khode S, Dwivedi RC. et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev 2009; 35 (08) 744-753
• 105 Hermans R. Posttreatment imaging in head and neck cancer. Eur J Radiol 2008; 66 (03) 501-511
• 106 Razfar A, Heron DE, Branstetter IV BF, Seethala RR, Ferris RL. Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 2010; 120 (04) 734-738